- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- This topic was presented to the Topic Selection Oversight Panel (TSOP) on March 2022 where it was agreed that a Technology Appraisal (TA) was not appropriate. Dulaglutide has been routed to NICE Centre for Guidelines where the topic will be considered for potential inclusion within the next review of NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management. Please note that timelines for a potential review of NG18: Diabetes (type 1 and type 2) in children and young people are to be confirmed. Please contact: [email protected] for further information
- ID number:
- 10660
Project Team
- Project lead
- [email protected]
Email enquiries
If you have any queries please email [email protected]
For further information on how we select topics for development, please see our page about prioritising our guidance topics